Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1991 1
1992 1
1993 2
1994 2
1995 3
1996 5
1997 4
1998 1
1999 4
2000 2
2001 1
2002 2
2003 2
2004 1
2005 2
2006 8
2007 2
2008 6
2009 4
2010 9
2011 10
2012 7
2013 11
2014 11
2015 15
2016 19
2017 9
2018 14
2019 12
2020 17
2021 22
2022 2
Text availability
Article attribute
Article type
Publication date

Search Results

183 results
Results by year
Filters applied: . Clear all
Page 1
Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party.
Schuurhuis GJ, Heuser M, Freeman S, Béné MC, Buccisano F, Cloos J, Grimwade D, Haferlach T, Hills RK, Hourigan CS, Jorgensen JL, Kern W, Lacombe F, Maurillo L, Preudhomme C, van der Reijden BA, Thiede C, Venditti A, Vyas P, Wood BL, Walter RB, Döhner K, Roboz GJ, Ossenkoppele GJ. Schuurhuis GJ, et al. Among authors: cloos j. Blood. 2018 Mar 22;131(12):1275-1291. doi: 10.1182/blood-2017-09-801498. Epub 2018 Jan 12. Blood. 2018. PMID: 29330221 Free PMC article. Review.
Cell sensitivity assays: the MTT assay.
van Meerloo J, Kaspers GJ, Cloos J. van Meerloo J, et al. Among authors: cloos j. Methods Mol Biol. 2011;731:237-45. doi: 10.1007/978-1-61779-080-5_20. Methods Mol Biol. 2011. PMID: 21516412
Molecular Minimal Residual Disease in Acute Myeloid Leukemia.
Jongen-Lavrencic M, Grob T, Hanekamp D, Kavelaars FG, Al Hinai A, Zeilemaker A, Erpelinck-Verschueren CAJ, Gradowska PL, Meijer R, Cloos J, Biemond BJ, Graux C, van Marwijk Kooy M, Manz MG, Pabst T, Passweg JR, Havelange V, Ossenkoppele GJ, Sanders MA, Schuurhuis GJ, Löwenberg B, Valk PJM. Jongen-Lavrencic M, et al. Among authors: cloos j. N Engl J Med. 2018 Mar 29;378(13):1189-1199. doi: 10.1056/NEJMoa1716863. N Engl J Med. 2018. PMID: 29601269 Free article.
The role of alternative splicing in cancer: From oncogenesis to drug resistance.
Sciarrillo R, Wojtuszkiewicz A, Assaraf YG, Jansen G, Kaspers GJL, Giovannetti E, Cloos J. Sciarrillo R, et al. Among authors: cloos j. Drug Resist Updat. 2020 Dec;53:100728. doi: 10.1016/j.drup.2020.100728. Epub 2020 Sep 28. Drug Resist Updat. 2020. PMID: 33070093 Free article. Review.
The war on clones: a Darwinian enigma.
Cloos J, Ossenkoppele GJ. Cloos J, et al. Blood. 2021 Jun 3;137(22):3008-3009. doi: 10.1182/blood.2021011150. Blood. 2021. PMID: 34081123 No abstract available.
Positioning of proteasome inhibitors in therapy of solid malignancies.
Roeten MSF, Cloos J, Jansen G. Roeten MSF, et al. Among authors: cloos j. Cancer Chemother Pharmacol. 2018 Feb;81(2):227-243. doi: 10.1007/s00280-017-3489-0. Epub 2017 Nov 28. Cancer Chemother Pharmacol. 2018. PMID: 29184971 Free PMC article. Review.
(Immuno)proteasomes as therapeutic target in acute leukemia.
Cloos J, Roeten MS, Franke NE, van Meerloo J, Zweegman S, Kaspers GJ, Jansen G. Cloos J, et al. Cancer Metastasis Rev. 2017 Dec;36(4):599-615. doi: 10.1007/s10555-017-9699-4. Cancer Metastasis Rev. 2017. PMID: 29071527 Free PMC article. Review.
Can we incorporate MRD assessment into clinical practice in AML?
Ossenkoppele G, Schuurhuis GJ, van de Loosdrecht A, Cloos J. Ossenkoppele G, et al. Among authors: cloos j. Best Pract Res Clin Haematol. 2019 Jun;32(2):186-191. doi: 10.1016/j.beha.2019.05.003. Epub 2019 May 10. Best Pract Res Clin Haematol. 2019. PMID: 31204000 Review.
Proteasome inhibitors in acute leukemia.
Niewerth D, Dingjan I, Cloos J, Jansen G, Kaspers G. Niewerth D, et al. Among authors: cloos j. Expert Rev Anticancer Ther. 2013 Mar;13(3):327-37. doi: 10.1586/era.13.4. Expert Rev Anticancer Ther. 2013. PMID: 23477519 Review.
Leukemic stem cells: identification and clinical application.
Hanekamp D, Cloos J, Schuurhuis GJ. Hanekamp D, et al. Among authors: cloos j. Int J Hematol. 2017 May;105(5):549-557. doi: 10.1007/s12185-017-2221-5. Epub 2017 Mar 29. Int J Hematol. 2017. PMID: 28357569 Review.
183 results